Literature DB >> 9143251

Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide.

B Devaux1, F Enderlin, B Wallner, D E Smilek.   

Abstract

Myelin oligodendrocyte glycoprotein (MOG) is a transmembrane glycoprotein expressed on the surface of central nervous system (CNS) myelin membranes, which has been shown to induce experimental autoimmune encephalomyelitis (EAE) in rodents. Here we describe the induction of EAE in SJL and (PLJ X SJL)F1 mice with truncated human recombinant MOG (thr-MOG, amino acids 1-120) which has been expressed in insect cells in soluble form. We show that in SJL mice, immunization with thr-MOG produces an immune response to the 1-30 and the 81-110 regions of the MOG molecule. We also demonstrate effective treatment of thr-MOG-induced EAE in SJL mice with intravenous injections of a single peptide, MOG 91-110. These results support the possibility of treating MS using an antigen dependent approach.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143251     DOI: 10.1016/s0165-5728(97)00019-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

Authors:  Dilip K Challa; Uta Bussmeyer; Tarique Khan; Héctor P Montoyo; Pankaj Bansal; Raimund J Ober; E Sally Ward
Journal:  MAbs       Date:  2013-06-19       Impact factor: 5.857

Review 2.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

3.  Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.

Authors:  Eric C Klawiter; Laura Piccio; Jeri-Anne Lyons; Robert Mikesell; Kevin C O'Connor; Anne H Cross
Journal:  Arch Neurol       Date:  2010-09

4.  Amelioration of EAE by a cryptic epitope of myelin oligodendrocyte glycoprotein.

Authors:  Jeri A Lyons; Melissa M Riter; Alaa M Almatrook; Michael J Ramsbottom; Anne H Cross
Journal:  J Neuroimmunol       Date:  2016-06-24       Impact factor: 3.478

5.  Adult spinal cord radial glia display a unique progenitor phenotype.

Authors:  Audrey Petit; Ashley D Sanders; Timothy E Kennedy; Wolfram Tetzlaff; Katie J Glattfelder; Rachel A Dalley; Ralph B Puchalski; Allan R Jones; A Jane Roskams
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

6.  'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides.

Authors:  Nathali Kaushansky; Nicole Kerlero de Rosbo; Rina Zilkha-Falb; Reut Yosef-Hemo; Lydia Cohen; Avraham Ben-Nun
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

7.  Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis.

Authors:  K L Legge; B Min; J J Bell; J C Caprio; L Li; R K Gregg; H Zaghouani
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307

Review 8.  Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.

Authors:  Patrick Peschl; Monika Bradl; Romana Höftberger; Thomas Berger; Markus Reindl
Journal:  Front Immunol       Date:  2017-05-08       Impact factor: 7.561

Review 9.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

Review 10.  B cell depletion therapies in autoimmune disease: advances and mechanistic insights.

Authors:  Dennis S W Lee; Olga L Rojas; Jennifer L Gommerman
Journal:  Nat Rev Drug Discov       Date:  2020-12-15       Impact factor: 84.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.